Business Context and Reporting Period
This Form 8-K Current Report is filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on June 24, 2026. The filing addresses the Company's compliance status with NYSE American continued listing standards regarding stockholders' equity.
Key Financial Metrics
- Stockholders' Equity: $3,022,000 as of March 31, 2026.
- Profitability Status: The Company reported losses from continuing operations and/or net losses in five of its most recent fiscal years ended December 31, 2025.
- Revenue, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for revenue, operating cash flow, debt levels, or liquidity ratios beyond the stockholders' equity figure.
Material Changes and Listing Status
The Company received a "June Notice" from the NYSE American on June 24, 2026, confirming non-compliance with two specific listing standards:
- Section 1003(a)(iii): Requires stockholders' equity of at least $6.0 million for companies with losses in their five most recent fiscal years.
- Section 1003(a)(ii): Requires stockholders' equity of at least $4.0 million for companies with losses in three of their four most recent fiscal years.
Previously, on April 3, 2026, the Company had received notice regarding the Section 1003(a)(iii) standard. The June Notice adds the Section 1003(a)(ii) non-compliance based on the March 31, 2026 equity balance.
Guidance, Outlook, and Risks
Compliance Plan: The Company submitted a plan to the NYSE American on May 4, 2026, which was accepted. The exchange granted a plan period extending through October 2, 2027, to regain compliance.
Operational Impact: The June Notice has no immediate impact on the listing or trading of the Company's common stock, which will continue to trade under the symbol "MTNB" on the NYSE American during the plan period. Ongoing business operations and SEC reporting requirements remain unaffected.
Risks: If the Company fails to regain compliance by the October 2, 2027 deadline, or fails to make progress consistent with the Plan, the NYSE American may initiate delisting proceedings. The filing includes standard forward-looking statement disclaimers regarding uncertainties in regaining compliance.
Investor Verification Checklist
- Verify the Company's progress reports submitted to the NYSE American during the plan period ending October 2, 2027.
- Review the specific actions outlined in the Plan submitted on May 4, 2026, to determine the strategy for increasing stockholders' equity.
- Monitor future filings for any updates on the Company's financial position, specifically regarding the reduction of accumulated losses or capital raising activities.
- Check for any subsequent notices from the NYSE American regarding the Company's compliance status prior to the plan period deadline.